§1 · The Synthesis Line
The dopamine factory, and where bromantane acts
Dopamine is manufactured in two enzymatic steps. Tyrosine hydroxylase (TH) — the rate-limiting step — converts the amino acid tyrosine into L-DOPA; DOPA-decarboxylase (DDC, also called AAAD) converts L-DOPA into dopamine. Stimulants of the amphetamine class act after this line, forcing stored dopamine out of vesicles. Bromantane acts on the line itself: it induces the expression of the genes for both enzymes.
The two-step dopamine synthesis line and bromantane's point of action. Scientific illustration — not experimental imagery.
§2 · The Core Finding
Gene expression first, dopamine second
The foundational study is Vakhitova and colleagues (2004): a single oral dose of ladasten in rat induced expression of the tyrosine hydroxylase and DOPA-decarboxylase genes in the striatum and hypothalamus, and the subsequent accumulation of L-DOPA and dopamine correlated with that transcriptional activation. The sequence matters — message first, enzyme second, transmitter third. This is de novo synthesis: the body making more of its own dopamine, on its own schedule. Animal
Mikhaylova and colleagues (2007) confirmed and extended the picture: differential upregulation of TH at both mRNA and protein level, with dopamine and L-DOPA rising across the ventral tegmental area, nucleus accumbens, hypothalamus, striatum and hippocampus. In the hippocampus, bromantane transformed short-term potentiation into long-term potentiation that depended on protein synthesis and D1/D5 receptors — it was blocked by anisomycin and by SCH23390. A genomic mechanism, writing itself into synaptic plasticity. Animal
§3 · The Epigenetic Footnote
A demethylated promoter
How does a small molecule raise a gene's expression? One correlate has been reported: cytosine demethylation in the TH gene promoter in rat hypothalamus (Vakhitova 2006, cited via the review literature). An epigenetic loosening of the promoter would fit the durable, non-exhaustive character of the effect — the enzyme machinery stays elevated rather than spiking and crashing. This is a single-thread finding and is presented at that weight. Animal Review
§4 · The Negative Space
What the mechanism is not
Precision about the unknowns is part of the monograph's discipline:
- Not a reuptake inhibitor at relevant concentrations. Microdialysis does show increased striatal dopamine release and metabolism (Grekhova 1995), but in-vitro monoamine reuptake inhibition requires 50–500 µM — orders of magnitude beyond clinical relevance. "Dopamine reuptake inhibitor" is a misdescription.
- The upstream trigger is unknown. Which receptor or target sits between the molecule and the gene expression remains unidentified; protein kinase A/C activation is implicated. Sigma-1 receptor agonism has been hypothesised for adamantanes generally but never demonstrated for bromantane, and this monograph does not assert it.
- Not exhaustive action. Unlike psychostimulants — amphetamine, methylphenidate, mesocarb — the actoprotector profile shows no hyperstimulation and no functional exhaustion after the effect, in keeping with a synthesis-side rather than release-side mechanism.
§5 · Secondary Threads
Beyond dopamine, at their proper weight
| Thread | Finding | Weight |
|---|---|---|
| GABA-ergic component | Strengthened GABA-ergic mediation and reduced GABA-transporter expression — the proposed basis of the anxiolytic-without-sedation profile | Review |
| Neurotrophins | Increased BDNF/NGF expression and MAP-kinase activation (Salimgareeva 2012) | Single source |
| Immunomodulation | B-cell increases after a single dose; T-cell normalisation in chronically stressed mice; lowered IL-6/IL-17 in an anxiety-depression model | Animal |
| Upstream molecular trigger | Unidentified; PKA/PKC implicated; sigma-1 hypothesised for adamantanes, not demonstrated for bromantane | Unknown |
How these mechanisms map onto each documented benefit area — and at which evidence tier — is laid out on Documented Effects.
§6 · Citations
References for this page
- Vakhitova IuV, Iamidanov RS, Seredinin SB. Ladasten induces the expression of genes regulating dopamine biosynthesis in various structures of rat brain. Eksp Klin Farmakol. 2004;67(4):7-11. PMID 15500036
- Mikhaylova M, Vakhitova JV, Yamidanov RS, et al. The effects of ladasten on dopaminergic neurotransmission and hippocampal synaptic plasticity in rats. Neuropharmacology. 2007;53(5):601-8. PMID 17854844
- Grekhova TV, et al. Effect of bromantane on the dopaminergic system of the striatum (microdialysis). Biull Eksp Biol Med. 1995;119(3):302-4. PMID 7795203
- Oliynyk S, Oh S. The pharmacology of actoprotectors. Biomol Ther (Seoul). 2012;20(5):446-56. PMC3762282
- Tallerova AV, et al. Bromantane immunomodulation studies. Bull Exp Biol Med. 2014;156(3):335-7. PMID 24771370